Dr. Bolu Ogunyemi Becomes New CMA President

Published Date: 08 Jun 2026

Bolu Ogunyemi, MD, dermatologist from St. John’s, Newfoundland and Labrador, has become the Canadian Medical Association’s first Black president and is among its youngest.

Read Full News

Latest News

Most OTC Vaginal Moisturizers Contain Contact Allergens

Over-the-counter vaginal and vulvar moisturizers often contain allergens, with inaccurate marketing claims, a study shows.

Takeda's AI-crafted Psoriasis Pill Tops Bristol Myers' Sotyktu in Head-to-head Trial

Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol ⁠Myers Squibb's approved drug...

Drop Flare Fears to Fix Rheumatic Vaccination Gaps

Vaccination remains the best measure to protect immunosuppressed patients, but new evidence suggests a rethink of scheduling.

Secondary Syphilis Sign Shows Reliable Histologic Pattern

Condyloma lata in secondary syphilis shows consistent histopathologic findings that may help prevent misdiagnosis.

Can Age-Old Chinese Therapy Reduce Insulin Needs in T2D?

Acupuncture may reduce insulin requirements to a greater extent than a sham treatment in adults with type 2 diabetes and overweight receiving insulin therapy, a trial suggests.

Golimumab Shows Benefit in Refractory HS

More than half of patients with treatment-refractory hidradenitis suppurativa achieve meaningful disease improvement with golimumab therapy in a study.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Latest News

Over-the-counter vaginal and vulvar moisturizers often contain allergens, with inaccurate marketing claims, a study shows.

Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol ⁠Myers Squibb's approved drug...

Vaccination remains the best measure to protect immunosuppressed patients, but new evidence suggests a rethink of scheduling.

Condyloma lata in secondary syphilis shows consistent histopathologic findings that may help prevent misdiagnosis.

Acupuncture may reduce insulin requirements to a greater extent than a sham treatment in adults with type 2 diabetes and overweight receiving insulin therapy, a trial suggests.

More than half of patients with treatment-refractory hidradenitis suppurativa achieve meaningful disease improvement with golimumab therapy in a study.

News All Time

Sacroiliitis Worsening Commonly Found in Psoriatic Arthritis

A new study has uncovered factors associated with sacroiliitis progression in patients with psoriatic arthritis, as well as protective factors such as use of biologic and targeted DMARDs.

Birch Extract Boosts Wound Healing in EB: Long-Term Data

Oleogel-S10 accelerates wound healing and reduces wound burden in children with epidermolysis bullosa, a study finds.

US CDC Flags Health Risks Linked to Travel-related Cosmetic Procedures

The U.S. Centers for Disease Control and Prevention said on Tuesday that many Americans suffered serious complications — ⁠including bacterial infections and, in some cases,...

Camp Victory: Support, Connections for Kids With Vitiligo

A unique camp brings together children and youth with vitiligo and their parents to talk about their challenges. They don’t want to leave.

Doctor Helps Woman Stop Blaming Herself and Accept Treatment

When an oncologist learns one patient’s story, everything shifts, including his approach to consultations.

IBS: New Dietetic Guidance Advises to ‘Think Beyond Diet’

Updated BDA guidance moves away from a diet-first approach to IBS, urging dietitians to consider lifestyle, mental health, and nondietary factors.

From K-pop to K-glow: Lasers, Face Firming Drive S Korea Tourism

Just over 2 million foreigners visited South Korea last year for medical treatment, nearly double the 2024 figure of ‌1.17 million.

Mohs for Rare Skin Cancer Linked to Lower Recurrence vs WLE

Mohs micrographic surgery reduces positive margins and 5-year recurrence in patients with dermatofibrosarcoma protuberans, compared with wide local excision, study finds.

The Potential for Remission, Cure in Psoriasis

'With the IL-23 blockers, for the first time ever, we've … seen a disconnect between drug levels in the blood and the ability to stay in remission,' says Andrew Blauvelt, MD.

Genital Lesions Most Common Sign of CCD

Most patients with cutaneous Crohn’s disease present with genital lesions and show good response with biologic therapy, according to a study shows.

FDA Approves OTC Switch for Topical Acne Treatment

The product combining adapalene 0.1% and benzoyl peroxide 2.5% was approved as a prescription acne treatment in December 2008 for patients aged 12 years and older.

Botulinum Toxin for Frown Lines Moves Toward EU Approval

EMA advisers have backed a botulinum toxin for moderate to severe frown lines in adults, with reported onset of action as early as 8 hours and effects lasting 2-3 weeks.

Epidermolysis Bullosa: New Therapies Bring Hope, Healing

FDA-approved EB therapies expand options for gene replacement and wound healing, but success depends on careful wound preparation and timing, experts say.

Expert Guidance on Stacking Systemic Therapies for Psoriasis

Advice on when and how to switch or stack treatments can help in cases of an incomplete or waning response.

Endocrine Disruptors: Could Exposure Affect Generations?

Clinicians are urged to consider cumulative endocrine disruptor exposure in patients with unexplained hormonal and metabolic symptoms.

EMA Backs First Drug for Severe Overgrowth Disorders

The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening PIK3CA-related overgrowth disorders.

Recommended News For You

Patients value communication skills from cancer surgeons across six key areas, according to research

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

a brand-new generic therapy for different types of cancer.

BTK Inhibitor Active in Half of Patients With Richter Transformation

Drop in credit score after cancer diagnosis linked to increased mortality

Recommended Articles For You

Surgery for Tracheoesophageal Fistula: What to Expect Before, During, and After  

Phosphate Vs. Phosphorus: What Is The Difference? 

Environmental Carcinogen Exposure Screening: Advances, Clinical Implications, and Guideline-Based Approaches 

Essential Developments in Oncology for Healthcare Excellence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EMA OKs Two Treatments for Small Cell Lung Cancer

2.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

3.

Cancer care crowdfunding increasingly common, but rarely successful

4.

A video animation guide to assist young people who are fatigued from cancer.

5.

Muscular strength and good physical fitness linked to lower risk of death in people with cancer

1.

Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored

2.

How EPCORITAMAB is Revolutionizing the Treatment of Cancer

3.

Exploring the Latest Treatments for Essential Thrombocythemia

4.

A New Perspective on Spherocytosis: Uncovering Innovative Treatments

5.

Modern Applications in Oncology in the Digital Era

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

3.

Efficient Management of First line ALK-rearranged NSCLC - Part V

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot